Skip to main content

komzifti

Generic: ziftomenib·Code: ziftomenib

komzifti: sourced relationships with 1 company · 1 FDA decision.

komzifti evidence translation

What we can confirm

What it means

Source-backed records connect komzifti to KURA; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could komzifti → KURA affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (1)
CompanyDated record stage
Kura Oncology, Inc. (KURA)
developer · Reported 2026-03-05 · Current development: unknownSource
Relapsed or refractory acute myeloid leukemia (AML) with a s…
Approved
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE KOMZIFTI is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment options [see Dosage and Administration ( 2.1 ), Clinical Pharmacology ( 12.1 ), and Clinical Studies ( 14 )] . KOMZIFTI is a menin inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment options. ( 1 )(KURA)FDA ↗
NDA220305Type 1 - New Molecular EntityOrphan DrugPriorityOralCapsule

Frequently asked questions

Which companies have sourced relationships with komzifti?

komzifti has dated SEC/FDA relationship records for Kura Oncology, Inc..

What is komzifti's latest FDA decision?

The most recent tracked FDA decision for komzifti is Approval for 1 INDICATIONS AND USAGE KOMZIFTI is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment options [see Dosage and Administration ( 2.1 ), Clinical Pharmacology ( 12.1 ), and Clinical Studies ( 14 )] . KOMZIFTI is a menin inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment options. ( 1 ), dated November 13, 2025.